Obalon Corporate

Extraordinarily experienced in healthcare innovation.

William J. Plovanic was promoted to President and Chief Executive Officer in October 2019. He joined Obalon in March 2016 as our Chief Financial Officer and was appointed as President and a Class I director in May 2019. Previously, Mr. Plovanic served as Managing Director, Medical Technology Equity Research at Canaccord Genuity Inc., an investment bank, from February 2007 to March 2016. Prior to Canaccord Genuity, Mr. Plovanic served in various roles at First Albany Capital Inc. from February 2001 to February 2007, including as Managing Director, Equity Research. Mr. Plovanic holds a B.S. from Bradley University and is a CFA Charterholder. Our Board believes that Mr. Plovanic’s deep knowledge and experience with our company and products, and his financial expertise, qualify him to serve on our Board.
Mark Brister has served as our Vice President of Research and Development since June 2008. Mr. Brister has an extensive history of developing novel technology platforms that have served as the foundation for creating successful companies. Mr. Brister was Vice President of R&D for DexCom, Inc., Vice President of Vascular R&D for Medtronic, Inc., and Vice President of R&D for Arterial Vascular Engineering.
Amy VandenBerg has served as our Chief Clinical & Regulatory Affairs Officer since December 2018. Ms. VandenBerg joined Obalon in 2008 as Director of Regulatory Affairs. Ms. VandenBerg has served as our Vice President of Regulatory Affairs since February 2012 and assumed the Vice President of Clinical and Regulatory Affairs position in November 2014. Prior to joining Obalon, Ms. VandenBerg held positions of increasing leadership at other medical device companies, including Dexcom, Inc. (NASDAQ:DXCM) and Cygnus. She has more than 20 years of experience with a focus on medical device quality systems, clinical affairs as well as domestic and international regulatory affairs in bringing novel and disruptive medical device technologies from the research and development phase through the US FDA PMA approval process.
Robert MacDonald has served as our Chief Retail Officer since May 30, 2019. Prior to joining us, Mr. MacDonald served as Vice President of Growth for Sono Bello, a cosmetic surgery company, from December 2016 to January 2019, where he was responsible for real estate, construction, staffing, and operational ramp-up for new clinics. During his tenure at Sono Bello, he also was responsible for the launch and testing of new products and services, including the Obalon balloon system. Prior to Sono Bello, Mr. MacDonald worked as Vice President of Technology Services for Staples, an office product company, from 2004 to 2011, and as Regional Vice President at McDonald’s from 1994 to 2004. He also has over 10 years of experience in management consulting with Ernst & Young and Oliver Wyman. Mr. MacDonald holds a B.A. degree in Economics from the University of Notre Dame, and he earned his M.B.A. from Harvard Business School.
Nooshin Hussainy was promoted to Chief Financial Officer in October 2019. She joined Obalon in December 2011 as our Vice President of Finance. Ms. Hussainy has over 20 years of experience in high growth companies ranging from Fortune 100 to venture-backed start-ups, including DexCom, Inc., GenMark Diagnostics, and Active Network. Ms. Hussainy has completed 2 IPOs in medical devices and diagnostics, secondary offerings, and debt offerings.

Visionaries with track records of success.

Andrew Rasdal has served as a member of our board of directors and as our President and Chief Executive Officer since June 2008. Mr. Rasdal brings more than 25 years of medical technology experience, including serving as CEO of DexCom, Inc., Senior Vice President and President of Vascular for Medtronic, Inc., and Vice President of Marketing for Arterial Vascular Engineering.
William J. Plovanic was promoted to President and Chief Executive Officer in October 2019. He joined Obalon in March 2016 as our Chief Financial Officer and was appointed as President and a Class I director in May 2019. Previously, Mr. Plovanic served as Managing Director, Medical Technology Equity Research at Canaccord Genuity Inc., an investment bank, from February 2007 to March 2016. Prior to Canaccord Genuity, Mr. Plovanic served in various roles at First Albany Capital Inc. from February 2001 to February 2007, including as Managing Director, Equity Research. Mr. Plovanic holds a B.S. from Bradley University and is a CFA Charterholder. Our Board believes that Mr. Plovanic’s deep knowledge and experience with our company and products, and his financial expertise, qualify him to serve on our Board.
Raymond Dittamore has served as a member of our board of directors since March 2016. Mr. Dittamore retired in June 2001 as a partner of Ernst & Young LLP, an international public accounting firm, after 35 years of service. Mr. Dittamore currently serves on the board of directors of QUALCOMM Incorporated, a semiconductor and telecommunications equipment company. Mr. Dittamore previously served on the boards of directors of Life Technologies Corporation, Gen-Probe Incorporation and Digirad Corporation.
David Moatazedi has served as a member of our board since March 2017. Mr. Moatazedi is currently Senior Vice President, U.S. Medical Aesthetics including Facial Aesthetics, Plastic Surgery and Regenerative Medicine, Body Contouring and Skincare, for Allergan plc, where he has worked in positions of increasing responsibility since March 2005. Prior to Allergan, Mr. Moatazedi held several positions at Novartis Pharmaceuticals, including District Manager from June 2002 to March 2005.
Douglas Fisher has served as a member of our board since May 2012. Dr. Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also serves as the Chief Business Officer at Sera Prognostics, Inc., where he has worked since January 2015. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006.
Les Howe has served as a member of our board of directors since January 2016. Mr. Howe served as the Chief Executive Officer of Consumer Networks LLC, an internet marketing and promotions company, from December 2001 to May 2007. From July 1967 to September 1997, Mr. Howe held several positions at KPMG Peat Marwick LLP, an international auditing and accounting firm, and served as area managing partner/managing partner of their Los Angeles office from May 1994 to September 1997.
Kim Kamdar, Ph.D. has served as a member of our board of directors since January 2008. Dr. Kamdar is currently a partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG.
Sharon Stevenson, DVM Ph.D. has served as a member of our board since January 2008. Dr. Stevenson is currently a Co-Founder and Managing Director of Okapi Venture Capital, a venture capital company, where she has worked since 2005. Prior to founding Okapi, Dr. Stevenson was the Senior Vice President of Technology and Planning for SkinMedica, Inc. (acquired by Allergan, Inc.) from 2003 to 2004. Prior to SkinMedica, Dr. Stevenson was a Principal with Domain Associates, LLC from 2000 to 2003. While at Domain, Dr. Stevenson also served as President and Chief Financial Officer of Volcano Corporation.

Deeply engaged in advancing healthcare.

Obalon Therapeutics, Inc was founded in 2008 and is backed by the following:

  • Domain Associates
  • InterWest Partners
  • Okapi Venture Capital
  • AmorePacific
  • Axon Ventures
  • Bader Sultan & Bros. Co. W.L.L.
  • Mirae Asset Venture Investment
  • NeoPlux Co., Ltd.
  • Striker Asia Opportunities Fund
  • Square 1 Bank
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling.